U.S. Markets open in 3 hrs 32 mins

Momenta Pharmaceuticals Inc (MNTA) Files 10-K for the Fiscal Year Ended on December 31, 2017

- By insider

Momenta Pharmaceuticals Inc (MNTA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Momenta Pharmaceuticals Inc is a biotechnology company. It is engaged in developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease. Momenta Pharmaceuticals Inc has a market cap of $1.37 billion; its shares were traded at around $18.00 with and P/S ratio of 11.83.


For the last quarter Momenta Pharmaceuticals Inc reported a revenue of $64.6 million, compared with the revenue of $34.20 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $138.9 million, an increase of 26.7% from last year. For the last five years Momenta Pharmaceuticals Inc had an average revenue growth rate of 25% a year.

The reported loss per diluted share was $1.2 for the year, compared with the loss per share of $1.91 in the previous year. The Momenta Pharmaceuticals Inc had an operating margin of -66.64%, compared with the operating margin of -68.17% a year before. The 10-year historical median operating margin of Momenta Pharmaceuticals Inc is -142.21%. The profitability rank of the company is 3 (out of 10).

At the current stock price of $18.00, Momenta Pharmaceuticals Inc is traded at close to its historical median P/S valuation band of $18.99. The P/S ratio of the stock is 11.83, while the historical median P/S ratio is 12.48. The stock gained 14.57% during the past 12 months.

CEO Recent Trades:

  • President & CEO Craig A Wheeler sold 3,938 shares of MNTA stock on 02/21/2018 at the average price of $16.46. The price of the stock has increased by 9.36% since.
  • President & CEO Craig A Wheeler sold 18,648 shares of MNTA stock on 02/14/2018 at the average price of $16.14. The price of the stock has increased by 11.52% since.
  • President & CEO Craig A Wheeler sold 10,406 shares of MNTA stock on 02/08/2018 at the average price of $15.89. The price of the stock has increased by 13.28% since.

CFO Recent Trades:

  • SVP, CFO Scott M Storer sold 3,972 shares of MNTA stock on 02/14/2018 at the average price of $15.16. The price of the stock has increased by 18.73% since.

Directors and Officers Recent Trades:

  • SVP & General Counsel Bruce Leicher sold 728 shares of MNTA stock on 02/21/2018 at the average price of $15.9. The price of the stock has increased by 13.21% since.
  • COO & CSO Ganesh Venkataraman Kaundinya sold 745 shares of MNTA stock on 02/21/2018 at the average price of $15.9. The price of the stock has increased by 13.21% since.
  • COO & CSO Ganesh Venkataraman Kaundinya sold 4,986 shares of MNTA stock on 02/14/2018 at the average price of $15.23. The price of the stock has increased by 18.19% since.
  • SVP & General Counsel Bruce Leicher sold 4,948 shares of MNTA stock on 02/14/2018 at the average price of $15.22. The price of the stock has increased by 18.27% since.
  • SVP & General Counsel Bruce Leicher sold 1,861 shares of MNTA stock on 02/08/2018 at the average price of $16. The price of the stock has increased by 12.5% since.

For the complete 20-year historical financial data of MNTA, click here.

This article first appeared on GuruFocus.